Investigations against AstraZeneca: ”Chinese interests may be behind them”

Why are there several investigations against AstraZeneca employees in China right now? Life Science Sweden continues to seek answers.

Discover Precision: Join ZEISS at the Control Fair in Stuttgart

May 6-9, 2025 in Stuttgart. Hall 9, Booth 9309.

Nytt AI-verktyg ska hjälpa forskare förstå varför läkemedel misslyckas

Ett nytt AI-verktyg ska lösa ett av läkemedelsutvecklingens stora utmaningar: patienter som inte svarar på sina behandlingar. Genom att koppla samman stora mäng...

Scilifelabs ordförande får förnyat förtroende

Ylva Engström fortsätter som ordförande för Scilifelabs. Hennes nya förordnande sträcker sig till 2027.

In-Depth Insights into the Most Useful ZEISS Metrology Expert Tips

Free webinar June 24th, 2025, 9:00-9:45 AM and 5:00-5:45 PM.

New Horizons in Biologics & Bioprocessing incl. Advanced Therapies: Copenhagen (2026)

How to Assure Quality within R&D Medical Devices

Free webinar on June 3rd, 2025, 9:00 - 9:45 AM CEST and 5:00 - 5:45 PM CEST.

Venomaid's rapid test aims to find the right snake bite treatment

Every six seconds, someone on our planet suffers a snake bite, and each time, a race against the clock begins. What kind of snake was it, and which antivenom ca...

Novo Nordisk appoints Mike Doustdar as new CEO

The Danish pharmaceutical giant Novo Nordisk has appointed Mike Doustdar as its new CEO. At the same time, the company announced it was lowering its forecasts –...

ZEISS unveils AI-powered Research Data Platform

Collaboration with Boehringer Ingelheim champions the future of personalized eye care.

Bioarctics forskningschef Johanna Fälting tar plats i VR:s ämnesråd

Bioarctics forskningschef Johanna Fälting och läkaren Markus Lingman har utsetts till nya ledamöter i Vetenskapsrådets ämnesråd för medicin och hälsa.

Government apoints new experts to medicine and health council

Johanna Fälting, Head of Research at BioArctic, and physician Markus Lingman have been appointed as new members of the Swedish Research Council’s Subject Counci...

Korbinian Löbmann leads scientific meeting on drug formulation: High activity in the field

Korbinian Löbmann has moderated New Updates in Drug Formulation & Bioavailability several times before. Now he is once again taking on the scientific meeting. L...

ZEISS Quality Innovations at CONTROL

May 6-9, 2025 in Stuttgart.

Security flaw in Swedish breast cancer screening software – woman passed away

A lack of safeguard in Sectra's software led to a woman with breast cancer receiving an incorrect diagnosis. She later passed away. The software is used in 20 o...

Meet us at Control 2025

Innovations that drive efficiency.

Icelandic pharmaceutical company Alvotech to list on Nasdaq Stockholm

One of Iceland's largest companies, the pharmaceutical firm Alvotech, has announced its intention to list on Nasdaq Stockholm.

Marie Gårdmark: “What to expect from Trump’s second term?”

One may complain about the complex multinational system in EU, but it gives us some predictability that cannot be easily overturned by different member states p...

“Don’t postpone the transition to IVDR”

Operators who have not yet started to adapt to the requirements of the new EU IVDR regulation are running out of excuses. This is the opinion of Helena Dzojic, ...

Ozempic may benefit hip replacement surgery

The high-profile drug for type 2 diabetes and weight loss may be beneficial in other areas. One such area is for patients undergoing hip replacement surgery, a ...

Partial court victory for entrepreneur who lost his company

Swedish life science entrepreneur Mikael Kubista has won the first round against a law firm that he, along with other co-owners, sued for negligent advice in co...

Miljardsatsning ska få forskare att lämna USA för EU

Vita husets krav på ökat inflytande över universiteten har väckt oro för hotad akademisk frihet. Nu ska en ny EU-förorning locka amerikanska forskare till Europ...

ZEISS introduces the new Smartzoom 100

The future of digital microscopy for efficient optical inspections.

AZ gets approval for drug targeting rare disease – it may reduce cortisone dependence

AstraZeneca’s drug Fasenra gets an expanded indication in the EU and is now approved as a treatment for the rare autoimmune disease known as Churg-Strauss syndrome.